The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir
Open accessAbstract
The influenza virus neuraminidase (NA) inhibitors zanamivir and oseltamivir were introduced into clinical practice in various parts of the world between 1999 and 2002. In order to monitor the potential development of resistance, the Neuraminidase Inhibitor Susceptibility Network was established to coordinate testing of clinical isolates collected through the World Health Organization influenza surveillance network from different regions of the world (M. Zambon and F. G. Hayden, Antivir. Res. 49:147-156, 2001). The present study establishes the baseline susceptibilities prior to and shortly after the introduction of the NA inhibitors. Over 1,000 clinical influenza isolates recovered from 1996 to 1999 were tested. Susceptibilities were determined by enzyme inhibition assays with chemiluminescent or fluorescent substrates with known NA inhibitor-resistant viruses as controls. The 50% inhibitory concentrations (IC 50 s) depended upon the assay method, the drug tested, and the influenza virus subtype. By both assays, the mean zanamivir IC 50 s were 0.76, 1.82, and 2.28 nM for the subtype H1N1 (N1), H3N2 (N2), and B NAs, respectively, and the oseltamivir IC 50 s were 1.2, 0.5, and 8.8 nM for the N1, N2, and B NAs, respectively. The drug susceptibilities of known zanamivir- and oseltamivir-resistant viruses with the NA mutations E119V, R292K, H274Y, and R152K fell well outside the 95% confidence limits of the IC 50 s for all natural isolates. Sequence analysis of the NAs of viruses for which the IC 50 s were above the 95% confidence limits and several control isolates for which the IC 50 s were in the normal range revealed variations in some previously conserved residues, including D151, A203, T225, and E375 (N2 numbering). Known resistance mutations are both influenza virus subtype and drug specific, but there was no evidence of naturally occurring resistance to either drug in any of the isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963036t · Cited by 1,100
Potier, M., Mameli, L., Bélisle, M., Dallaire, L., & Melançon, S. B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90362-2 · Cited by 815
Options for the control of influenza III
Ada, G. L., Tannock, G. A., & Hampson, A. W. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00191-0 · Cited by 587
Self-citationEvidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus
Gubareva, L. V., Matrosovich, M. N., Brenner, M. K., Bethell, R. C., & Webster, R. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/314440 · Cited by 432
Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families
Hayden, F. G., Belshe, R. B., Clover, R. D., Hay, A. J., Oakes, M. G., & Soo, W. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912213212502 · Cited by 416
Self-citationIves, J. A. L., Carr, J. A., Mendel, D. B., Tai, C. Y., Lambkin, R., Kelly, L., Oxford, J. S., Hayden, F. G., & Roberts, N. A. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00053-0 · Cited by 379
Self-citationInhaled Zanamivir for the Prevention of Influenza in Families
Hayden, F. G., Gubareva, L. V., Monto, A. S., Klein, T. C., Elliott, M. J., Hammond, J. M., Sharp, S. J., & Ossi, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431801 · Cited by 371
Self-citationResistance of influenza viruses to neuraminidase inhibitors — a review
MCKIMMBRESCHKIN, J. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00103-0 · Cited by 320
Self-citationSelection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with Oseltamivir
Gubareva, L. V., Kaiser, L., Matrosovich, M. N., Soo‐Hoo, Y., & Hayden, F. G. (2001) · The Journal of Infectious Diseases · doi:10.1086/318537 · Cited by 318
Self-citationThree-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2·2 Å resolution
Varghese, J. N., & Colman, P. M. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)80068-6 · Cited by 230
Gubareva, L. V., Robinson, M. J., Bethell, R. C., & Webster, R. G. (1997) · Journal of Virology · doi:10.1128/jvi.71.5.3385-3390.1997 · Cited by 212
Wetherall, N. T., Trivedi, T., Zeller, J., Hodges-Savola, C., McKimm-Breschkin, J. L., Zambon, M., & Hayden, F. G. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.2.742-750.2003 · Cited by 207
Self-citationGubareva, L. V., Webster, R. G., & Hayden, F. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3403-3408.2001 · Cited by 203
Self-citationMcKimm-Breschkin, J. L., Sahasrabudhe, A., Blick, T. J., McDonald, M., Colman, P. M., Hart, G. J., Bethell, R. C., & Varghese, J. N. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2456-2462.1998 · Cited by 183
Self-citationEnglund, J. A., Champlin, R. E., Wyde, P. R., Kantarjian, H., Atmar, R. L., Tarrand, J., Yousuf, H., Regnery, H., Klimov, A. I., Cox, N. J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516358 · Cited by 162
Self-citationInfluenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets
Herlocher, M. L., Carr, J., Ives, J., Elias, S., Truscon, R., Roberts, N. A., & Monto, A. S. (2002) · Antiviral Research · doi:10.1016/s0166-3542(01)00214-5 · Cited by 158
Position statement: global neuraminidase inhibitor susceptibility network
Zambon, M. C. F. A., & Hayden, F. G. (2001) · Antiviral Research · doi:10.1016/s0166-3542(01)00124-3 · Cited by 155
Self-citationBantia, S., Parker, C. D., Ananth, S. L., Horn, L. L., Andries, K., Chand, P., Kotian, P. L., Dehghani, A., El-Kattan, Y. A., Lin, T., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1162-1167.2001 · Cited by 151
Low Incidence of Rimantadine Resistance in Field Isolates of Influenza A Viruses
Ziegler, T. T., Hemphill, M. L., Ziegler, M., Perez‐Oronoz, G., Klimov, A. I., Hampson, A. W., Regnery, H. L., & Cox, N. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/314994 · Cited by 113
Self-citationBoivin, G., Goyette, N., Hardy, I., Aoki, F. Y., Wagner, A., & Trottier, S. (2000) · The Journal of Infectious Diseases · doi:10.1086/315392 · Cited by 76
Management of Influenza: Use of New Antivirals and Resistance in Perspective
Jackson, H. C., Roberts, N. A., Wang, Z. M., & Belshe, R. B. (2000) · Clinical Drug Investigation · doi:10.2165/00044011-200020060-00007 · Cited by 68
Treatment of influenza with neuraminidase inhibitors: virological implications
Roberts, N. A. (2001) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2001.1002 · Cited by 65
Amantadine-Resistant Influenza A in Nursing Homes
Houck, P. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430050113012 · Cited by 60
Ghate, A. A., & Air, G. M. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2580320.x · Cited by 54
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
Antiviral agents active against influenza A viruses
De Clercq, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2175 · Cited by 668
Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., & Gubareva, L. V. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-08 · Cited by 480
Self-citationDrug resistance in influenza A virus: the epidemiology and management
Hussain, M., Galvin, H., Haw, T. Y., Nutsford, A., & Husain, M. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s105473 · Cited by 439
Metadata
- Authors
- McKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., & Zambon, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-07
- Volume
- 47
- Issue
- 7
- Pages
- 2264-2272
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2156231263
- Cited by
- 291
- References
- 25
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.